The Net Margin of Amarin Corporation PLC (AMRN) is
-18.16%.
Net Margin measures the percentage of net income derived from total revenue after all expenses. It signals how much actual profit a company retains from its sales.
| Date |
Value |
| 2025-12-31 |
-18.16%
|
| 2024-12-31 |
-35.95%
|
| 2023-12-31 |
-19.26%
|
| 2022-12-31 |
-28.66%
|
| 2021-12-31 |
1.32%
|
| 2020-12-31 |
-2.93%
|
| 2019-12-31 |
-5.26%
|
| 2018-12-31 |
-50.79%
|
| 2017-12-31 |
-37.49%
|
| 2016-12-31 |
-66.41%
|
| Ticker |
Name |
Value |
|
AKBA
|
Akebia Therapeutics Inc
|
-2.26%
|
|
SRNE
|
Sorrento Therapeutics Inc
|
-912.10%
|
|
ACAD
|
Acadia Pharmaceuticals Inc.
|
36.49%
|
|
EGRX
|
Eagle Pharmaceuticals Inc
|
11.24%
|
|
MDGL
|
Madrigal Pharmaceuticals, Inc.
|
-30.08%
|
|
PTCT
|
PTC Therapeutics, Inc.
|
39.44%
|
|
CBPO
|
China Biologic Products Holdings Inc
|
29.04%
|
|
EDIT
|
Editas Medicine, Inc.
|
-395.01%
|
|
HZNP
|
Horizon Therapeutics PLC
|
14.37%
|
|
CDMO
|
Avid Bioservices Inc
|
-100.60%
|
|
ESPR
|
Esperion Therapeutics, Inc.
|
-5.63%
|
|
ICPT
|
Intercept Pharmaceuticals Inc
|
77.64%
|
|
PRTA
|
Prothena Corporation PLC
|
-2520.57%
|
|
AGIO
|
Agios Pharmaceuticals, Inc.
|
-764.01%
|
|
BCRX
|
BioCryst Pharmaceuticals, Inc.
|
30.16%
|
|
CHRS
|
Coherus Oncology Inc
|
398.43%
|
|
HRTX
|
Heron Therapeutics Inc
|
-13.04%
|
|
INSM
|
Insmed Incorporated
|
-210.54%
|
|
MDXG
|
MiMedx Group, Inc.
|
11.60%
|
|
ENTA
|
Enanta Pharmaceuticals Inc
|
-125.36%
|
|
ORGO
|
Organogenesis Holdings Inc.
|
6.56%
|
|
PGEN
|
Precigen, Inc.
|
-2588.21%
|
|
SRRK
|
Scholar Rock Holding Corporation
|
-405.21%
|
|
VCEL
|
Vericel Corporation
|
5.98%
|
|
ALKS
|
Alkermes Plc
|
16.37%
|
|
MGNX
|
MacroGenics Inc
|
-49.91%
|
|
MORF
|
Morphic Holding Inc
|
-29192.90%
|
|
XNCR
|
Xencor, Inc.
|
-73.20%
|
|
ZNTL
|
Zentalis Pharmaceuticals, Inc.
|
-245.96%
|
|
MYGN
|
Myriad Genetics, Inc.
|
-44.38%
|
|
TVTX
|
Travere Therapeutics, Inc.
|
-5.21%
|